Amelia Clark, NP
Nurse Practitioner · Billings, MTNPI 1073244596
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,117 of the $1,272 with a category attached, or 87.8%. 12 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 39.5% of the total. Reporting peaked in 2023 at $848 and has fallen 74.5% since, to $216 in 2025. Among nurse practitioner clinicians in MT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 32 payments — averaging $39.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$502
- AstraZeneca$156
- Sanofi$123
- Grifols USA, LLC$108
- GSK$92
- Boehringer Ingelheim$83
- plus $207 from 6 others
What the payments were for
- Food & beverage$1,11788%
- Education$15512%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 8 | $502 |
| AstraZeneca | 6 | $156 |
| Sanofi | 1 | $123 |
| Grifols USA, LLC | 1 | $108 |
| GSK | 3 | $92 |
| Boehringer Ingelheim | 4 | $83 |
| Edwards Lifesciences | 1 | $69 |
| Philips North America LLC | 3 | $49 |
| Harmony Biosciences LLC | 2 | $29 |
| Novartis | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Amgen | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,272 in reported general payments places this provider in the 90th percentile of 357 nurse practitioner providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 18 | $234,525 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 193 | $222,832 |
| Fasenra PenBenralizumab | 13 | $68,922 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 88 | $63,753 |
| Spiriva RespimatTiotropium Bromide | 79 | $49,660 |
| Breo ElliptaFluticasone/Vilanterol | 71 | $45,179 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 42 | $26,672 |
| DuleraMometasone/Formoterol | 48 | $15,770 |
| Advair HfaFluticasone Propion/Salmeterol | 28 | $12,608 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $11,008 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $10,562 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $9,195 |
| Incruse ElliptaUmeclidinium Bromide | 24 | $8,927 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 43 | $7,548 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 50 | $7,327 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $83 | $321,419156 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $92 | $288,486317 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $156 | $74,761118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 357 nurse practitioner providers in Montana.
Other nurse practitioner in Billings
- Jennifer TerrellBillings$7K
- Amanda Abrams-BuerkleyBillings$6K
- Andrea LappBillings$4K
- Lisa PrincipeBillings$2K
- Marcus NicolaBillings$2K
- Jodi GilliganBillings$700
- Mary BrownBillings$680
- Melissa FullerBillings$630
- Kristen BeckBillings$595
- Lindsay CantwellBillings$584
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.